Blockchain Registration Transaction Record

Oncotelic's IV Everolimus Cuts Gut Toxicity by 67-Fold in New Data

Oncotelic Therapeutics reveals new data showing its IV everolimus formulation reduces gastrointestinal toxicity by 67-fold vs oral version, potentially improving cancer treatment tolerability and efficacy.

This development matters because it addresses a critical limitation of current cancer therapies. Everolimus is an important drug used to treat various cancers, but its oral formulation often causes severe gastrointestinal side effects—like mouth sores, diarrhea, and nausea—due to excessive drug accumulation in the gut. These side effects can force dose reductions or treatment discontinuations, compromising patient outcomes and quality of life. By dramatically reducing GI exposure through an intravenous formulation, Oncotelic's approach could make everolimus more tolerable, allowing patients to receive full, consistent doses without debilitating side effects. This could improve treatment adherence, potentially enhance survival rates, and set a precedent for reformulating other oncology drugs to minimize toxicity. For the biopharmaceutical industry, it represents an innovative strategy to optimize existing therapies, potentially accelerating development timelines compared to creating entirely new drugs.